{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:24:39Z","timestamp":1787315079583,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.pupt.2020.101899","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T20:40:49Z","timestamp":1579552849000},"page":"101899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life"],"prefix":"10.1016","volume":"61","author":[{"given":"Bruno","family":"Sposato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianna","family":"Camiciottoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Scalese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna Elisiana","family":"Carpagnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Pelaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierachille","family":"Santus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Maniscalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Masieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Corsico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Scichilone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Baglioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Murgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Folletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Bardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cameli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Latorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Musarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bargagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolamo","family":"Pelaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Paggiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pupt.2020.101899_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.pupt.2020.101899_bib2","doi-asserted-by":"crossref","first-page":"100032","DOI":"10.1016\/j.waojou.2019.100032","article-title":"Prevalence of severe asthma according to the drug regulatory agency perspective: an Italian experience","volume":"12","author":"Vianello","year":"2019","journal-title":"World Allergy Organ. J."},{"key":"10.1016\/j.pupt.2020.101899_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40733-016-0029-3","article-title":"Asthma costs and social impact","volume":"3","author":"Nunes","year":"2017","journal-title":"Asthma Res. Pract."},{"issue":"6","key":"10.1016\/j.pupt.2020.101899_bib4","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.anai.2019.08.462","article-title":"Evaluating direct costs and productivity losses of asthma patients receiving GINA 4\/5 therapy in the US","volume":"123","author":"Settipane","year":"2019","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"8","key":"10.1016\/j.pupt.2020.101899_bib5","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.jaip.2019.05.053","article-title":"Proportion of severe asthma patients eligible for mepolizumab therapy by age and age of onset of asthma","volume":"7","author":"Comberiati","year":"2019","journal-title":"J. Allergy Clin. Immunol. In Pract."},{"key":"10.1016\/j.pupt.2020.101899_bib6","author":"Global Initiative for Asthma"},{"issue":"13","key":"10.1016\/j.pupt.2020.101899_bib7","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"MENSA Investigators, Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"9842","key":"10.1016\/j.pupt.2020.101899_bib8","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.pupt.2020.101899_bib9","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"SIRIUS Investigators, Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.pupt.2020.101899_bib10","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin. Therapeut."},{"issue":"1","key":"10.1016\/j.pupt.2020.101899_bib11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12890-018-0689-2","article-title":"Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response","volume":"18","author":"Drick","year":"2018","journal-title":"BMC Pulm. Med."},{"issue":"1","key":"10.1016\/j.pupt.2020.101899_bib12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.18176\/jiaci.0285","article-title":"Prospective open-label study of 48-week subcutaneous administration of mepolizumab in Japanese patients with severe eosinophilic asthma","volume":"29","author":"Kurosawa","year":"2019","journal-title":"J Investig. Allergol. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.pupt.2020.101899_bib13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40413-018-0210-7","article-title":"The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials","volume":"11","author":"Bagnasco","year":"2018","journal-title":"World Allergy Organ. J."},{"issue":"October","key":"10.1016\/j.pupt.2020.101899_bib14","doi-asserted-by":"crossref","first-page":"101836","DOI":"10.1016\/j.pupt.2019.101836","article-title":"One year of mepolizumab. Efficacy and safety in real-life in Italy","volume":"58","author":"Bagnasco","year":"2019","journal-title":"Pulm. Pharmacol. Therapeut."},{"issue":"December","key":"10.1016\/j.pupt.2020.101899_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2018.09.006","article-title":"Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: results of a single-centre observational study","volume":"53","author":"Pelaia","year":"2018","journal-title":"Pulm. Pharmacol. Therapeut."},{"issue":"Sep 3","key":"10.1016\/j.pupt.2020.101899_bib16","first-page":"1","article-title":"Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma","author":"Pertzov","year":"2019","journal-title":"J. Asthma"},{"issue":"Oct","key":"10.1016\/j.pupt.2020.101899_bib17","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.rmed.2013.05.003","article-title":"Techniques for assessing small airways function: possible applications in asthma and COPD","volume":"119","author":"Konstantinos Katsoulis","year":"2016","journal-title":"Respir. Med."},{"issue":"6","key":"10.1016\/j.pupt.2020.101899_bib18","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.jaci.2015.10.029","article-title":"Forced midexpiratory flow between 25% and 75% of forced vital capacity is associated with long-term persistence of asthma and poor asthma outcomes","volume":"137","author":"Siroux","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"issue":"Mar","key":"10.1016\/j.pupt.2020.101899_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.rmed.2019.01.016","article-title":"Mepolizumab improves small airway function in severe eosinophilic asthma","volume":"148","author":"Farah","year":"2019","journal-title":"Respir. Med."},{"issue":"4","key":"10.1016\/j.pupt.2020.101899_bib20","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","article-title":"The minimally important difference of the Asthma Control Test","volume":"124","author":"Schatz","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.pupt.2020.101899_bib21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1164\/rccm.201611-2232PP","article-title":"Eosinophilic and noneosinophilic asthma","volume":"197","author":"Carr","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.pupt.2020.101899_bib22","doi-asserted-by":"crossref","first-page":"E1375","DOI":"10.3390\/jcm8091375","article-title":"Severe eosinophilic asthma","volume":"8","author":"Bakakos","year":"2019","journal-title":"J. Clin. Med."},{"issue":"Feb","key":"10.1016\/j.pupt.2020.101899_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.rmed.2018.12.009","article-title":"Eosinophilic airway inflammation is a main feature of unstable asthma in adolescents","volume":"147","author":"Ci\u00f3\u0142kowski","year":"2019","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.pupt.2020.101899_bib24","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.jaip.2019.03.006","article-title":"Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes","volume":"7","author":"Sposato","year":"2019","journal-title":"J. Allergy Clin. Immunol. In Pract."},{"issue":"1","key":"10.1016\/j.pupt.2020.101899_bib25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/MCP.0000000000000541","article-title":"Oral corticosteroid-dependent asthma: current knowledge and future needs","volume":"25","author":"Pavord","year":"2019","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"Jun","key":"10.1016\/j.pupt.2020.101899_bib26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pupt.2017.03.004","article-title":"Xolair Italian Study Group, Can the response to Omalizumab be influenced by treatment duration? A real-life study","volume":"44","author":"Sposato","year":"2017","journal-title":"Pulm. Pharmacol. Therapeut."},{"issue":"8","key":"10.1016\/j.pupt.2020.101899_bib27","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40273-018-0658-x","article-title":"Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations","volume":"36","author":"McQueen","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.pupt.2020.101899_bib28","article-title":"Update: mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use","volume":"Sep 14","author":"Albers","year":"2019","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.pupt.2020.101899_bib29","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/all.13850","article-title":"The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma","volume":"74","author":"Chapman","year":"2019","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.pupt.2020.101899_bib30","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/all.12914","article-title":"Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment","volume":"71","author":"Magnan","year":"2016","journal-title":"Allergy"},{"issue":"Jun 5","key":"10.1016\/j.pupt.2020.101899_bib31","article-title":"Efficacy of mepolizumab in patients with previous omalizumab treatment failure: real-life observation","author":"Bagnasco","year":"2019","journal-title":"Allergy"}],"container-title":["Pulmonary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553919302949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553919302949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:28:57Z","timestamp":1761082137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553919302949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":31,"alternative-id":["S1094553919302949"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2020.101899","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2020.101899","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101899"}}